Literature DB >> 19828305

Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease.

Sumit R Majumdar1, Cristina Villa-Roel, Kristin J Lyons, Brian H Rowe.   

Abstract

OBJECTIVES: Patients with COPD are at risk for osteoporosis-related vertebral compression fractures (VCF) which predispose to more fractures and worsening pulmonary function. Our objectives were to: 1 document VCF prevalence in COPD patients; and 2 determine the independent correlates of VCF.
METHODS: From 2004-2006, we prospectively recruited consecutive consenting COPD patients presenting with acute exacerbation at three Canadian Emergency Departments (ED). We collected clinical and pulmonary function data. Primary outcome was radiologist documented VCF on chest radiograph. Multivariable logistic regression was used for all adjusted analyses.
RESULTS: Overall, 245 patients were studied; 37% were >or=75 years and 44% were women. Prevalence of VCF documented by chest radiograph was 22 of 245 (9%; 95%CI 6-13%). Almost half (10 of 22 [43%]) of VCF patients were not treated for osteoporosis and all 10 received oral steroids. Compared to patients without fractures, those with VCF were older (p=0.014), had COPD of longer duration (p=0.09) and greater severity (mean FEV(1) 0.9 vs 1.1L; p=0.05), and had lower body mass index [BMI] (median 26 vs 28; p=0.01). Across BMI quartiles (from heaviest [median 37] to lightest [median 21]) the prevalence of VCF progressively increased (2%, 8%, 10%, 21%; p<0.001). In analyses adjusted for age, sex, and COPD duration, the only independent correlate of VCF was BMI: VCF increased as BMI decreased from heaviest (OR=1) to lightest (OR=11.0) quartiles (p=0.025).
CONCLUSIONS: Almost one-tenth of COPD patients presenting with acute exacerbation have chest radiographs documenting VCF. About half of patients with VCF were not treated for osteoporosis, but all were started on oral steroids. Our findings suggest chest radiograph reports may represent an important case-finding tool for VCF, particularly in underweight patients with COPD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828305     DOI: 10.1016/j.rmed.2009.09.013

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  18 in total

1.  COPD and osteoporosis: something more than a comorbidity.

Authors:  Claudio Tantucci
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

Review 2.  Inflammatory diseases and bone fragility.

Authors:  K Briot; P Geusens; I Em Bultink; W F Lems; C Roux
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

Review 3.  Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives.

Authors:  Daniel J Hassett; Michael T Borchers; Ralph J Panos
Journal:  J Microbiol       Date:  2014-03-01       Impact factor: 3.422

4.  Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function.

Authors:  Reiko Watanabe; Takeshi Tanaka; Keisuke Aita; Masaaki Hagiya; Toshiaki Homma; Kyoko Yokosuka; Hisami Yamakawa; Tsutomu Yarita; Nobuyuki Tai; Junko Hirano; Daisuke Inoue; Ryo Okazaki
Journal:  J Bone Miner Metab       Date:  2014-07-05       Impact factor: 2.626

5.  Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids.

Authors:  D Brask-Lindemann; P Eiken; P Eskildsen; B Abrahamsen
Journal:  Osteoporos Int       Date:  2012-11-14       Impact factor: 4.507

6.  Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.

Authors:  K R Olsen; C Hansen; B Abrahamsen
Journal:  Osteoporos Int       Date:  2013-04-20       Impact factor: 4.507

7.  Inhaled glucocorticoids are associated with vertebral fractures in COPD patients.

Authors:  Pedro Assed Gonçalves; Rafael Dos Santos Neves; Leonardo Vieira Neto; Miguel Madeira; Fernando Silva Guimarães; Laura Maria Carvalho Mendonça; Agnaldo Jose Lopes; Maria Lucia Fleiuss Farias
Journal:  J Bone Miner Metab       Date:  2017-08-01       Impact factor: 2.626

Review 8.  Osteoporosis in chronic obstructive pulmonary disease.

Authors:  Malay Sarkar; Rajeev Bhardwaj; Irappa Madabhavi; Jasmin Khatana
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-03-12

9.  [Osteoporosis in pneumological diseases : Joint guideline of the Austrian Society for Bone and Mineral Research (ÖGKM) and the Austrian Society for Pneumology (ÖGP)].

Authors:  Christian Muschitz; Ralf Harun Zwick; Judith Haschka; Hans Peter Dimai; Martina Rauner; Karin Amrein; Robert Wakolbinger; Peter Jaksch; Ernst Eber; Peter Pietschmann
Journal:  Wien Klin Wochenschr       Date:  2021-06-16       Impact factor: 1.704

Review 10.  Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.

Authors:  Julia Ae Walters; Daniel J Tan; Clinton J White; Richard Wood-Baker
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.